Patient characteristics that may favor RT over systemic therapies for adjuvant treatment include lack of a targetable BRAF mutation, high risk of toxicity to systemic therapies including those with a history of autoimmune disease, and/or patient preference. Here, BRAF is linked to autoimmune disease.